articleTop 1% cited
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.
The Lancet Oncology · 2011 · Vol. 12(8) · pp. 773–784
B Coiffier✉E.A. OsmanovXin HongAdriana ScheligaJiřı́ MayerF. OffnerSimon RuleAdriana TeixeiraJan WalewskiShoko VosMichael CrumpOfer ShpilbergDL EsseltineE. ZhuChristopher EnnyPanteli TheocharousHelgi van de VeldeY. A. ElsayedPier Luigi ZinzaniLym study investigatorsMarina. Liberati Anna
Lymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders researchMedicineRituximabBortezomibFollicular lymphomaOncologyInternal medicineLymphomaMultiple myeloma
Citations
1,622
FWCI
39.58
field-weighted impact
References
0
Percentile
100%
vs. same field & year
Citations per year
Cited by
Treatment of gastric cancer
World Journal of Gastroenterology · 2014 · 626 citations
Vascular Permeability and Drug Delivery in Cancers
Frontiers in Oncology · 2013 · 341 citations
Related articles
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.